Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 3/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 12/20 | 0.39 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.36 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31482149 | 0.94 | ADRA1A (0.46) | ADRA2CADRA1AACKR3L3MBTL3L3MBTL1 | |
| SCHEMBL31482176 | 0.93 | ADRA1A (0.39) | ADRA2CADRA1AACKR3L3MBTL3L3MBTL1 | |
| SCHEMBL31482186 | 0.90 | ADRA1A (0.38) | ADRA2CADRA1AACKR3L3MBTL3L3MBTL1 | |
| SCHEMBL31482199 | 0.89 | ACKR3 (0.38) | ADRA2CADRA1AACKR3L3MBTL3L3MBTL1 | |
| SCHEMBL31482220 | 0.88 | ADRA1A (0.37) | ADRA2CADRA1AACKR3L3MBTL3L3MBTL1 | |
| SCHEMBL31482237 | 0.88 | ADRA1A (0.37) | ADRA2CADRA1AACKR3L3MBTL3L3MBTL1 | |
| SCHEMBL31482141 | 0.88 | ACKR3 (0.37) | ADRA2CADRA1AACKR3L3MBTL3L3MBTL1 | |
| SCHEMBL31482088 | 0.87 | ACKR3 (0.39) | ADRA1AACKR3L3MBTL3L3MBTL1MEN1 | |
| SCHEMBL31482226 | 0.86 | ADRA1A (0.46) | ADRA1AACKR3 | |
| SCHEMBL31482212 | 0.86 | ADRA1A (0.46) | ADRA1AACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025068514-A1 | SUBSTITUTED HETEROCYCLIC CARBOXAMINDES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2025-04-03 | — | — | WO | disclosed |